| Ticker Symbol: | CEPH |
|---|---|
| Exchange: | NASD |
| Contact Info: | 41 Moores Road Frazer PA 19355 610 344-0200 |
| CEO/President: | Frank Baldino Jr. |
| Industry: | Medical - Biomedical / Standard Industry Code: 2834 |
| Description: | Cephalon is an international biopharmaceutical company focused on thediscovery, development and marketing of products to treat sleep disorders,neurological disorders, cancer and pain. In addition to an active research and development program, they market products in the United States and various countries in Europe. |
| Shares Outstanding: | 67,740 (000) | Market Value: | 4,500,340 ($000) |
|---|---|---|---|
| Percentage of Inst.Shareholders: | 14.22% | Number of Inst.Shareholders: | 3.70% |
| Last Quarter Sales: | 492.71 ($Mil.) | Last Quarter Net Income: | 60.07 ($Mil.) |
| Last Quarter EPS: | 1.13 | P/E Ratio: | 17 |
| Most Recent Earnings: | 1.12 on 05/01/08 | Earnings Per Share: | -2.00 |
| Most Recent Split: | Annual Dividend Rate: | 0 | |
| Most Recent Dividend: | Annual Dividend Yield: | 0% |


| AMGEN | +14.00 | 58.89 | |
| GILEAD SCIENCES | -0.20 | 45.75 | |
| GENENTECH INC | +16.10 | 87.53 | |
| CELGENE CP | -14.40 | 60.46 | |
| BIOGEN IDEC INC | -16.30 | 50.50 |
